Psoriatic Arthritis: key endpoint results by drug

The key endpoints of Psoriatic Arthritis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Psoriatic Arthritis page.

ACR20

ACR20 in Psoriatic Arthritis: 19 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept39.4%22.3%+17.1wk 24 · n 213NCT01860976 Phase 3, primary
apremilast38.1%19%+19.130 mg · wk 16 · n 168NCT01172938 Phase 3, primary
bimekizumab62.2%23.8%+38.4160 mg Q4W · wk 16 · n 431NCT03895203 Phase 3, secondary
brodalumab41.8%24.7%+17.1210 mg · wk 16 · n 146NCT02024646 Phase 3, primary
certolizumab pegol51.9%24.3%+27.6400 mg Q4W · wk 12 · n 135NCT01087788 Phase 3, primary
deucravacitinib52.9%31.8%+21.16 mg · wk 16 · n 70NCT03881059 Phase 2, primary
etanercept60.9%50.7% (Methotrexate)—wk 24 · n 284NCT02376790 Phase 3, primary
golimumab45.2%8.8%+36.4100 mg · wk 14 · n 146NCT00265096 Phase 3, primary
guselkumab52%22.2%+29.8100 mg q8w · wk 24 · n 127NCT03162796 Phase 3, primary
infliximab86.3%66.7% (Methotrexate)—wk 16 · n 51NCT00367237 Phase 3, primary
ixekizumab53.3%19.5%+33.880 mg Q4W · wk 24 · n 122NCT02349295 Phase 3, primary
netakimab82%a9%+73wk 24NCT03598751 Phase 3, primary
risankizumab61.9%35.7%+26.2150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171 Phase 2, primary
secukinumab59.5%27.4%+32.1150 mg without load · wk 16 · n 222NCT02404350 Phase 3, primary
tildrakizumab0.8%0.5%+0.3I · wk 24 · n 78NCT02980692 Phase 2, primary
tofacitinib50.5%33.3%+17.15 mg twice daily · wk 12 · n 107NCT01877668 Phase 3, primary
upadacitinib70.6%36.2%+34.415 mg · wk 12 · n 429NCT03104400 Phase 3, primary
ustekinumab49.5%22.8%+26.790 mg · wk 24 · n 204NCT01009086 Phase 3, primary
zasocitinib35.2%29.2%+6wk 12 · n 71NCT05153148 Phase 2, primary

Drugs checked with no result here: 27 not reported, 2 not posted, 4 trial running.

ACR50

ACR50 in Psoriatic Arthritis: 13 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
apremilast16.1%6%+10.130 mg · wk 16 · n 168NCT01172938 Phase 3, secondary
bimekizumab43.9%10%+33.9160 mg Q4W · wk 16 · n 431NCT03895203 Phase 3, primary
deucravacitinib24.3%10.6%+13.76 mg · wk 16 · n 70NCT03881059 Phase 2, secondary
etanercept40.4%16.9% (Methotrexate)—wk 12 · n 284NCT02376790 Phase 3, secondary
golimumab43.6%6.3%+37.3wk 14 · n 241NCT02181673 Phase 3, secondary
guselkumab20.5%10.3%+10.2100 mg q8w · wk 12 · n 127NCT03162796 Phase 3, secondary
ixekizumab35.2%5.1%+30.180 mg Q4W · wk 24 · n 122NCT02349295 Phase 3, secondary
risankizumab23.8%11.9%+11.9150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171 Phase 2, secondary
secukinumab31.4%6.3%+256 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205 Phase 3, primary
tofacitinib28.0%9.5%+18.55 mg twice daily · wk 13 · n 107NCT01877668 Phase 3, secondary
upadacitinib37.5%13.2%+24.315 mg · wk 12 · n 429NCT03104400 Phase 3, secondary
ustekinumab27.9%8.7%+19.290 mg · wk 24 · n 204NCT01009086 Phase 3, secondary
zasocitinib15.5%9.7%+5.8wk 12 · n 71NCT05153148 Phase 2, secondary

Drugs checked with no result here: 29 not reported, 6 not posted, 4 trial running.

PASI 75

PASI 75 in Psoriatic Arthritis: 12 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
apremilast25.6%11.2%+14.430 mg · wk 24 · n 90NCT01212770 Phase 3, secondary
bimekizumab68.8%10%+58.8160 mg · wk 12 · n 16NCT02969525 Phase 2, secondary
certolizumab pegol60.5%15.1%+45.4400 mg Q4W · wk 24 · n 76NCT01087788 Phase 3, secondary
deucravacitinib42.4%20.4%+226 mg · wk 16 · n 59NCT03881059 Phase 2, secondary
golimumab58.3%2.5%+55.8100 mg · wk 14 · n 108NCT00265096 Phase 3, secondary
guselkumab75.6%14.1%+61.5100 mg q8w · wk 24 · n 82NCT03162796 Phase 3, secondary
ixekizumab57.4%10.4%+4780 mg Q4W · wk 12 · n 68NCT02349295 Phase 3, secondary
secukinumab48.3%16.3%+32150 mg s.c. · wk 24 · n 58NCT01752634 Phase 3, secondary
tofacitinib42.7%14.6%+28.15 mg twice daily · wk 13 · n 82NCT01877668 Phase 3, secondary
upadacitinib62.6%21.3%+41.315 mg · wk 16 · n 214NCT03104400 Phase 3, secondary
ustekinumab62.4%11%+51.490 mg · wk 24 · n 149NCT01009086 Phase 3, secondary
zasocitinib25.6%15.4%+10.2wk 12 · n 39NCT05153148 Phase 2, secondary

Drugs checked with no result here: 28 not reported, 8 not posted, 4 trial running.

Minimal disease activity

Minimal disease activity in Psoriatic Arthritis: 12 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab41.5%13.1% (MTX)—wk 16 · n 123NCT02814175 Phase 4, primary
apremilast33.9%16%+17.930 mg · wk 16 · n 203NCT03747939 Phase 4, primary
bimekizumab45%13.2%+31.8160 mg Q4W · wk 16 · n 431NCT03895203 Phase 3, secondary
deucravacitinib22.9%7.6%+15.36 mg · wk 16 · n 70NCT03881059 Phase 2, secondary
etanercept35.9%22.9% (Methotrexate)—wk 24 · n 284NCT02376790 Phase 3, secondary
golimumab55.8%58.5% (Methotrexate)—wk 24 · n 43NCT04108468 Phase 3, secondary
guselkumab22.8%11.1%+11.7100 mg q8w · wk 24 · n 127NCT03162796 Phase 3, secondary
ixekizumab27.9%3.4%+24.580 mg Q4W · wk 24 · n 122NCT02349295 Phase 3, secondary
secukinumab22.4%5.3%+17.26 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205 Phase 3, secondary
upadacitinib36.6%12.3%+24.315 mg · wk 24 · n 429NCT03104400 Phase 3, secondary
ustekinumab22.2%35.7% (Secukinumab)—wk 28 · n 63NCT04632927 Phase 3, secondary
zasocitinib18.3%12.5%+5.8wk 12 · n 71NCT05153148 Phase 2, secondary

Drugs checked with no result here: 30 not reported, 6 not posted, 4 trial running.

HAQ-DI, change

HAQ-DI, change in Psoriatic Arthritis: 15 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab-0.5-0.3 (MTX)—wk 16 · n 116NCT02814175 Phase 4, secondary
apremilast-0.3-0.1−0.230 mg · wk 24 · n 161NCT01172938 Phase 3, secondary
bimekizumab-0.3-0.1−0.2160 mg Q4W · wk 16 · n 431NCT03895203 Phase 3, secondary
certolizumab pegol-0.5-0.2−0.3400 mg Q4W · wk 24 · n 135NCT01087788 Phase 3, secondary
deucravacitinib-0.4-0.1−0.36 mg · wk 16 · n 70NCT03881059 Phase 2, secondary
etanercept-0.4-0.4 (Methotrexate)—wk 24 · n 284NCT02376790 Phase 3, secondary
golimumab0.40+0.4100 mg · wk 24 · n 146NCT00265096 Phase 3, secondary
guselkumab-0.3-0.1−0.2100 mg q8w · wk 24 · n 127NCT03162796 Phase 3, secondary
ixekizumab-0.6-0.2−0.480 mg Q4W · wk 24 · n 122NCT02349295 Phase 3, secondary
risankizumab-0.2-0.1−0.1150 mg weeks 0, 4, and 16 · wk 16 · n 40NCT02719171 Phase 2, secondary
secukinumab-0.5-0.3−0.2150 mg s.c. · wk 24 · n 95NCT01752634 Phase 3, secondary
tofacitinib-0.3-0.2−0.25 mg twice daily · wk 12 · n 107NCT01877668 Phase 3, primary
upadacitinib-0.4-0.1−0.315 mg · wk 12 · n 404NCT03104400 Phase 3, secondary
ustekinumab-0.4-0.1−0.390 mg · wk 24 · n 204NCT01009086 Phase 3, secondary
zasocitinib-0.3-0.2−0.1wk 12 · n 66NCT05153148 Phase 2, secondary

Drugs checked with no result here: 28 not reported, 5 not posted, 4 trial running.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 52 approved or late-stage drugs with a featured trial in Psoriatic Arthritis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.